search

Active clinical trials for "Thyroid Neoplasms"

Results 1-10 of 654

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

Recruiting23 enrollment criteria

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient...

Atypical Teratoid/Rhabdoid TumorEpithelioid Sarcoma16 more

This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that that has either come back (relapsed) or does not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Recruiting94 enrollment criteria

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded...

CarcinomaNon-Small-Cell Lung1 more

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Recruiting15 enrollment criteria

Cancer and Blood Pressure Management, CARISMA Study

Cardiovascular DisorderChronic Kidney Disease7 more

This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor cancer therapy. This study is being done to find out if a systolic blood pressure to a target of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors understand the best way to control blood pressure in kidney or thyroid cancer patients taking anti-angiogenic tyrosine kinase inhibitor.

Recruiting29 enrollment criteria

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive...

Non-Small Cell Lung CancerMedullary Thyroid Cancer2 more

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Recruiting39 enrollment criteria

Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma

Papillary Thyroid MicrocarcinomaThyroid Cancer

This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.

Recruiting13 enrollment criteria

Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma

Papillary Microcarcinoma of the Thyroid

The primary objective of this study is to evaluate the outcome of two treatment approaches (immediate surgery or close follow-up) in patients with papillary thyroid microcarcinoma (mPTc) .

Recruiting10 enrollment criteria

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS...

Malignant Solid NeoplasmRecurrent Adrenal Gland Pheochromocytoma39 more

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Recruiting60 enrollment criteria

Safety of Endoscopic Thyroidectomy Via Retro-Auricular Single-Site Approach, Transoral Approach...

Papillary Thyroid Carcinoma

The goal of this retrospective study is to compare the safety and efficiacy of endoscopic thyroidectomy via retro-auricular single-site approach, transoral endoscopic thyroidectomy vestibular approach and transareola approach.

Recruiting10 enrollment criteria

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroid CancerThyroid Carcinoma4 more

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

Recruiting52 enrollment criteria
12...66

Need Help? Contact our team!


We'll reach out to this number within 24 hrs